NASDAQ:GRCE Grace Therapeutics Q4 2026 Earnings Report $2.43 +0.10 (+4.29%) Closing price 04:00 PM EasternExtended Trading$2.44 +0.01 (+0.41%) As of 04:21 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. ProfileEarnings HistoryForecast Grace Therapeutics EPS ResultsActual EPSN/AConsensus EPS -$0.24Beat/MissN/AOne Year Ago EPSN/AGrace Therapeutics Revenue ResultsActual RevenueN/AExpected Revenue$0.90 millionBeat/MissN/AYoY Revenue GrowthN/AGrace Therapeutics Announcement DetailsQuarterQ4 2026Date6/22/2026TimeBefore Market OpensConference Call DateTuesday, June 23, 2026Conference Call Time9:30AM ETConference Call ResourcesEarnings HistoryCompany Profile Grace Therapeutics Earnings HeadlinesGRCE Investors Have Opportunity to Join Grace Therapeutics, Inc. Fraud Investigation with the Schall Law FirmMay 27 at 11:33 AM | businesswire.comGrace Therapeutics (NASDAQ:GRCE) Rating Lowered to "Sell" at Wall Street ZenMay 23, 2026 | americanbankingnews.comI was right about SpaceXJeff Brown predicted Bitcoin before it climbed as high as 52,400%, Tesla before 2,150%, and Nvidia before 32,000%. Now he says SpaceX is shaping up to be the biggest IPO of the decade - and three key milestones just confirmed it. In the past 21 days: SpaceX crossed 10,000 active satellites, Elon filed confidential IPO paperwork with the SEC, and another rocket launched 25 more satellites. Two-thirds of every satellite in orbit now belongs to one company. The public filing could drop any day.May 28 at 1:00 AM | Brownstone Research (Ad)Grace Therapeutics (NASDAQ:GRCE) Trading 2.8% Higher - Time to Buy?May 22, 2026 | americanbankingnews.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Grace Therapeutics, Inc. - GRCEMay 21, 2026 | prnewswire.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Grace Therapeutics, Inc. - GRCEMay 19, 2026 | globenewswire.comSee More Grace Therapeutics Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Grace Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Grace Therapeutics and other key companies, straight to your email. Email Address About Grace TherapeuticsGrace Therapeutics (NASDAQ:GRCE) (NASDAQ: GRCE) is a clinical-stage biotechnology company dedicated to the discovery and development of novel therapies for rare genetic diseases. By employing a proprietary platform that integrates advanced molecular biology and biologic engineering, the company focuses on identifying and optimizing gene-based and protein-based candidates designed to address well-defined genetic drivers of disease. The company’s pipeline features multiple preclinical programs targeting lysosomal storage disorders and other inherited metabolic conditions. Through in-house capabilities and strategic partnerships with academic institutions and contract research organizations, Grace Therapeutics advances its candidates from target identification through lead optimization with the goal of accelerating entry into formal regulatory pathways. Based in the United States, Grace Therapeutics serves a global patient community by collaborating with development partners worldwide. The management team combines experience in drug discovery, clinical development and regulatory affairs, positioning the company to navigate the complex requirements of orphan drug designation and clinical trial execution. With a focus on innovation and strategic alliances, Grace Therapeutics aims to deliver transformative treatments for patients affected by rare genetic disorders.View Grace Therapeutics ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Snowflake and the Snowballing Impact of its AI FlywheelThis Quantum Computing Stock May Be Closer to a Breakout Than You ThinkMicrosoft Is Spending Billions on AI, But Investors Aren’t Buying ItSemtech’s Explosive Rally May Only Be Getting StartedBath & Body Works Stock Surged Despite Falling Sales—Here’s WhyAbercrombie Rallies as Strong Q1 Earnings Extend Winning StreakDick’s Sporting Goods Isn’t Done Winning Yet Upcoming Earnings Palo Alto Networks (6/2/2026)Broadcom (6/3/2026)CrowdStrike (6/3/2026)Medtronic (6/3/2026)Ciena (6/4/2026)Oracle (6/10/2026)Adobe (6/11/2026)Accenture (6/18/2026)FedEx (6/23/2026)Micron Technology (6/24/2026) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
